181 related articles for article (PubMed ID: 24980822)
1. An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine.
Maldonado L; Brait M; Michailidi C; Munari E; Driscoll T; Schultz L; Bivalacqua T; Schoenberg M; Sidransky D; Netto GJ; Hoque MO
Oncotarget; 2014 Jul; 5(14):5218-33. PubMed ID: 24980822
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine.
Hayashi M; Bernert H; Kagohara LT; Maldonado L; Brait M; Schoenberg M; Bivalacqua T; Netto GJ; Koch W; Sidransky D; Hoque MO
Oncotarget; 2014 May; 5(10):3350-61. PubMed ID: 24830820
[TBL] [Abstract][Full Text] [Related]
3. A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade.
Hermanns T; Savio AJ; Olkhov-Mitsel E; Mari A; Wettstein MS; Saba K; Bhindi B; Kuk C; Poyet C; Wild PJ; Noon A; Bashir S; Juvet T; Rendon RA; Waltregny D; van der Kwast T; Finelli A; Kulkarni GS; Fleshner NE; Lo K; Bapat B; Zlotta AR
Urol Oncol; 2020 Jun; 38(6):603.e1-603.e7. PubMed ID: 32081560
[TBL] [Abstract][Full Text] [Related]
4. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
[TBL] [Abstract][Full Text] [Related]
5. A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence.
Su SF; de Castro Abreu AL; Chihara Y; Tsai Y; Andreu-Vieyra C; Daneshmand S; Skinner EC; Jones PA; Siegmund KD; Liang G
Clin Cancer Res; 2014 Apr; 20(7):1978-89. PubMed ID: 24691641
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive prediction of recurrence in bladder cancer by detecting somatic TERT promoter mutations in urine.
Descotes F; Kara N; Decaussin-Petrucci M; Piaton E; Geiguer F; Rodriguez-Lafrasse C; Terrier JE; Lopez J; Ruffion A
Br J Cancer; 2017 Aug; 117(4):583-587. PubMed ID: 28683471
[TBL] [Abstract][Full Text] [Related]
7. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study.
Kavalieris L; O'Sullivan P; Frampton C; Guilford P; Darling D; Jacobson E; Suttie J; Raman JD; Shariat SF; Lotan Y
J Urol; 2017 Jun; 197(6):1419-1426. PubMed ID: 27986532
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
Kinde I; Munari E; Faraj SF; Hruban RH; Schoenberg M; Bivalacqua T; Allaf M; Springer S; Wang Y; Diaz LA; Kinzler KW; Vogelstein B; Papadopoulos N; Netto GJ
Cancer Res; 2013 Dec; 73(24):7162-7. PubMed ID: 24121487
[TBL] [Abstract][Full Text] [Related]
9. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer.
Brait M; Begum S; Carvalho AL; Dasgupta S; Vettore AL; Czerniak B; Caballero OL; Westra WH; Sidransky D; Hoque MO
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2786-94. PubMed ID: 18843024
[TBL] [Abstract][Full Text] [Related]
10. Validation of methylation markers for diagnosis of oral cavity cancer.
Arantes LM; de Carvalho AC; Melendez ME; Centrone CC; Góis-Filho JF; Toporcov TN; Caly DN; Tajara EH; Goloni-Bertollo EM; Carvalho AL;
Eur J Cancer; 2015 Mar; 51(5):632-41. PubMed ID: 25686481
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of DNA methylation in promoter regions of hTERT, TWIST1, VIM and NID2 genes in Moroccan bladder cancer patients.
El Azzouzi M; El Ahanidi H; Hafidi Alaoui C; Chaoui I; Benbacer L; Tetou M; Hassan I; Bensaid M; Oukabli M; Ameur A; Al Bouzidi A; El Mzibri M; Attaleb M
Cancer Genet; 2022 Jan; 260-261():41-45. PubMed ID: 34922269
[TBL] [Abstract][Full Text] [Related]
12. Comparison of promoter hypermethylation pattern in salivary rinses collected with and without an exfoliating brush from patients with HNSCC.
Sun W; Zaboli D; Liu Y; Arnaoutakis D; Khan T; Wang H; Koch W; Khan Z; Califano JA
PLoS One; 2012; 7(3):e33642. PubMed ID: 22438973
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples.
Renard I; Joniau S; van Cleynenbreugel B; Collette C; Naômé C; Vlassenbroeck I; Nicolas H; de Leval J; Straub J; Van Criekinge W; Hamida W; Hellel M; Thomas A; de Leval L; Bierau K; Waltregny D
Eur Urol; 2010 Jul; 58(1):96-104. PubMed ID: 19674832
[TBL] [Abstract][Full Text] [Related]
14. Promoter methylation of cyclin A1 is associated with human papillomavirus 16 induced head and neck squamous cell carcinoma independently of p53 mutation.
Weiss D; Basel T; Sachse F; Braeuninger A; Rudack C
Mol Carcinog; 2011 Sep; 50(9):680-8. PubMed ID: 21563216
[TBL] [Abstract][Full Text] [Related]
15. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance in substaging ofT1 urinary bladder urothelial carcinoma on transurethral resection.
Chang WC; Chang YH; Pan CC
Am J Surg Pathol; 2012 Mar; 36(3):454-61. PubMed ID: 22261706
[TBL] [Abstract][Full Text] [Related]
17. TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers.
Costa VL; Henrique R; Danielsen SA; Eknaes M; Patrício P; Morais A; Oliveira J; Lothe RA; Teixeira MR; Lind GE; Jerónimo C
Epigenetics; 2011 Sep; 6(9):1120-30. PubMed ID: 21847011
[TBL] [Abstract][Full Text] [Related]
18. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
Fantony JJ; Longo TA; Gopalakrishna A; Owusu R; Lance RS; Foo WC; Inman BA; Abern MR
Cancer Biomark; 2017; 18(4):381-387. PubMed ID: 28106542
[TBL] [Abstract][Full Text] [Related]
19. CCNA1 gene as a potential diagnostic marker in papillary thyroid cancer.
da Silva RM; Santos JN; Uno M; Chammas R; Kulcsar MAV; Sant'Anna LB; Canevari RA
Acta Histochem; 2020 Dec; 122(8):151635. PubMed ID: 33007517
[TBL] [Abstract][Full Text] [Related]
20. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
